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Abstract
Background: The origin of the reduction in thyroid uptake after a low activity iodine scan, so-called stunning effect,
is still controversial. Two explanations prevail: an individual cell stunning that reduces its capability to store iodine
without altering its viability, and/or a significant cell-killing fraction that reduces the number of cells in the tissue still
taking up iodine. Our aim is to analyze whether this last assumption could explain the observed reduction.
Methods: The survival fraction after administration of a small radioiodine activity was computed by two
independent methods: the application of the statistical theory underlying tissue control probability on recent clinical
studies of thyroid remnant 131I ablation and the use of the radiosensitivities reported in human thyroid cell assays for
different radioiodine isotopes.
Results: Both methods provided survival fractions in line with the uptake reduction observed after a low 131I activity
scan. The second method also predicts a similar behavior after a low 123I or 124I activity scan.
Conclusions: This study shows that the cell-killing fraction is sufficient to explain the uptake reduction effect for 131I
and 123I after a low activity scan and that even if some still living cells express a stunning effect just after irradiation
(as shown in vitro), they will mostly die with time. As the β/α value is very low, this therapy fractionation should not
impact the patient outcome in agreement with recent studies. However, in case of huge uptake heterogeneity, pre-
therapy scan could specifically kills high-uptake cells and by the way could reduce the cross irradiation to the low-
uptake cells during the therapy, resulting in a reduction of the ablation success rate.
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Background
The so-called thyroid stunning effect refers to the ob-
served fact that the 131I uptake at therapy is lower than
the one predicted from a 131I pre-therapeutic scan, even
when using a low activity such as 74 MBq [1–7]. In
addition to a reduction of the iodine uptake at 24 h, a
reduction of the effective half-life was also reported [7].
The explanation for this uptake reduction is still contro-
versial [8–14]. In vitro studies suggest that irradiation
may perturb cell metabolism before cell viability [15],
specifically by a downregulation of the sodium/iodide
symporter (NIS) expression at the transcription level
[16, 17], resulting in a reduction of the capacity to trans-
port iodine. Others suggest that this reduction could
purely result from killed cells that are thus no longer
present for (or able of ) keeping accumulated iodine [9].
The first hypothesis really corresponds to a cell stun-
ning, while the latter one corresponds to a therapy
fractionation.
A lower, but still actual uptake reduction was also ob-
served by Hilditch et al. [6] after administering 200 MBq
of 123I. To explain this fact, the authors also suggested a
self-stunning effect occurring during the 131I therapy
itself. The rationale is that in average 123I delivers 80
times less Gy per GBq than 131I due to its shorter
half-life and its lower electron emission energy [18].
However, Lundh et al. [19] showed in thyroid cells assays
that the relative biological effectiveness (RBE) of 123I was
about 5-fold higher than that of 131I, and thus an uptake
reduction induced by a low 123I activity cannot a priori
be rejected.
The aim of this study is to determine whether the
cell-killing fraction can quantitatively explain the
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uptake reductions of thyroid remnants reported after a
low activity pre-therapeutic scan using either radio-
iodines (131I, 123I) [6, 7]. The survival fraction, or
equivalently the cell-killing fraction, was computed by
two independent approaches: analyzing data reported
in recent thyroid ablation studies [20–24] with the
statistical theory underlying the tissue control probabil-
ity (TCP) [25], and using the radiosensitivities mea-
sured in human thyroid cell assays performed on both
normal and malignant lines [26] and the mean absorbed
doses reported in clinical studies [7]. In addition, the
second computation is also presented in Additional file
1 for a heterogeneous absorbed dose distribution as
observed on 124I PET scans [27].
Methods
Pure statistical analysis
Simply assuming Poisson statistics, Brahme and Agren
[25] deduced for TCP (initially named eradication prob-
ability), a relation that is known widely accepted [28, 29]:
TCP Að Þ ¼ e−Nc Sf D Að Þð Þ ð1Þ
where A is the administered activity, D(A) is the
absorbed dose in the tissue, Sf is the cell surviving frac-
tion, and Nc is the number of cells alive before
irradiation.
As beta-particles present a low linear energy transfer
(LET) and as the effective half-life of 131I in thyroid is
sufficiently large to result in low dose rate, the survival
fraction Sf can be approximated by:
Sf D Að Þð Þ ¼ e−αD Að Þ ð2Þ
where α is the cell radiosensitivity.
Therapeutics 131I activities still correspond to chemical
traces (less than 0.5 μg), thus for each patient, the
absorbed dose is proportional to the administered activity,
and Sf can be rewritten as:
Sf D Að Þð Þ ¼ e−α^ A ð3Þ
In addition to the cells radiosensitivity α, the param-
eter α^ also takes into account the uptake and the S
factor of the thyroid remnant.
Recent studies [20–24] using a single administration
of 1.11 GBq of 131I report thyroid remnant control prob-
abilities ranging from 70 to 95 %, i.e.,
TCP 1:11GBqð Þ∈ 0:70; 0:95½  ð4Þ
Thyroid cells radiosensitivity
Gaussen et al. [26] measured thyroid normal and tumor
cells radiosensitivities for low LET from 60Co irradiation
of 15 cell cultures (5 normal, 6 papillary carcinoma,
1 follicular carcinoma, 3 macrofollicular adenoma, com-
ing from 11 patients). These assays analyzed according
to the linear-quadratic model showed that α ranged from
0.37 Gy−1 (most radioresistant tumor cells) up to
0.97 Gy−1 (most radiosensitive normal cells), with a very
low β/α value. As beta particles also present a low LET,
these α values measured for 60Co can be used for 131I as
recommended by ICRP [30]. Furthermore, the quadratic
term can be neglected, validating the use of Eq. (2).
Lundh et al. [19] showed in thyroid cells assays that the
relative biological effectiveness (RBE) of 123I versus 131I
was about 5-fold, resulting in α value for 123I ranging
from 1.9 to 4.9 Gy−1. This can be explained by the larger
LET of 123I Auger electrons as compared to that of
higher energy 131I beta particles. In addition, a higher
LET also induces an even lower β/α value [31].
Cell survival fraction in thyroid remnants
As thyroid remnants are an unknown mix of normal
and tumor cells, the cell survival fraction was estimated
within the measured range of α values.
Lassman et al. [7] measured the uptake in the thyroid
remnants of six patients in two consecutive scans after
administration of 74 MBq of 131I (delay 4–6 weeks).
They found that the absorbed dose at the first scan
ranged from 4 to 38 Gy, corresponding to 0.15 and
1.70 % of the administered activity per gram of tissue,
together with a biological half-life larger than 40 days.
Rescaled to the standard thyroid mass (20 g), this gives
an uptake ranging from 3 to 34 %. This is in line with
iodide biokinetics reported from ICRP model giving an
uptake of 33 % for a normal thyroid and a biological
half-life of 80 days [32].
Hilditch et al. [6] reported the therapeutic to diagnostic
uptake ratio of thyroid remnants in 26 and 16 patients
using 120 MBq of 131I and 200 MBq of 123I for the diag-
nostic scan, respectively. As the thyroid remnant uptakes
were not reported, we estimated the cell survival fraction
by taking also into account the variability of uptake in thy-
roid remnants derived in the previous paragraph from [7].
As the biological half-life (>40 days) is much larger
than the 124I and 123I physical half lives, i.e., 4.18 and
0.55 days, these latter values were used as the effective
half-lives in the absorbed dose computation.
Results
Pure statistical analysis
Straight inversion of Eq. 1 gives
Sf Að Þ ¼ − ln TCP Að Þð Þ
Nc
ð5Þ
For 0.02 to 2 g of thyroid remnant, i.e., Nc ∈ [107, 109]
[33], Eqs. 4, 5 give
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Sf 1:11 GBqð Þ∈ 5:1 10−10; 3:6 10−8  ð6Þ
Note that, due to the random nature of energy depos-
ition in cells by the beta particles, a value Nc × Sf signifi-
cantly lower than one is needed to get more than 70 %
of chance to kill all the cells.
Combining Eqs. 3 and 6, we can write
Sf 74MBqð Þ ¼ e−α 74MBq ¼ e−α 1:11GBq 74=1110
¼ Sf 1:11 GBqð Þð Þ1=15∈ 24%; 32%½  ð7Þ
As a result of the 15th root, the survival fraction for
74 MBq only slightly varies in the range of TCP values
reported after administration of 1.11 GBq of 131I.
The same computation for 120 MBq of 131I gives
Sf 120 MBqð Þ∈ 10%; 16%½  ð8Þ
Figure 1 shows the predicted survival fraction Sf and
the TCP for 107 and 109 cells as functions of the dimen-
sionless variable α^A . Note that this figure depends only
on the number of cells ,Nc, in the tissue to be controlled
and not on the cell type. This last feature only modifies
the value of α^ , or in the other words, the corresponding
activity A needed to control the tissue.
Radiobiological analysis
Table 1 shows the mean absorbed dose and the cell
survival fraction computed assuming uniform absorbed
dose for the pre-therapeutic activities administered in
Sgouros et al. [27], Lassmann et al. [7], and Hilditch et
al. [6]. The mean absorbed dose D was computed using
Olinda [18]. Lowest and highest mean absorbed dose
values correspond to the minimal and maximal thyroid
remnants uptake observed in [7], i.e., 0.15 and 1.7 %/g,
respectively. Lowest and highest (italicized in Table 1)
cell survival fractions were derived from the combin-
ation of the maximal and minimal (italicized in Table 1)
absorbed dose and α values, respectively.
Discussion
Two independent formalisms show that the cell-killing
fraction is sufficient to explain the observed iodine uptake
reduction after a first pre-therapy scan, i.e., (1) a statistical
analysis based on Poisson statistics and on the remnant
control probability reported in recent clinical studies, and
(2) a radiobiological analysis using normal and cancer
thyroid cells radiosensitivity assays data jointly with the
uptake non-uniformity observed in 124I PET.
Note that such explanation of the uptake reduction by
cells killing is not incompatible with studies reporting a
decrease of the uptake reduction when the delay be-
tween the two scans increases [34, 35]. Indeed, after ir-
radiation, a fraction of the surviving cells will proliferate
with time and by the way the iodine uptake will also
re-increase with time.
The pure statistical analysis shows that, contrary to a
commonly accepted opinion, small activities of 131I such
as 74 or 120 MBq, i.e., one order of magnitude smaller
than those used for therapy, already kill in average about
Fig. 1 Predicted survival fraction (Eq. 3) and TCP (Eq. 1) for 107 and 109 cells as functions of the dimensionless variable α^A. Note that an activity
15 times lower than that needed to ensure a TCP between 70 and 95 % already kills about 75 % of the cells. The figure depends only on the
cells number ,Nc, present in the tissue to be controlled and not on their type. The cell type only modifies the value of α^ , i.e., the corresponding
activity A needed to control the tissue. 107 and 109 cells typically correspond to thyroid remnants total weight ranging from 0.02 to 2 g
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75 or 87 % of the remnant cells, respectively. This is suf-
ficient to explain the mean uptake reduction, i.e., 56 %
for 74 MBq and 67 % for 120 MBq, observed by Lass-
man et al. [7] and by Hilditch et al. [6], respectively.
Equation 1 involves that a probability of 70 % of ablating
a 1 g of tissue requires a survival fraction lower than 10−9.
This corresponds to absorbed doses far above those that
already kill a significant fraction of cells as shown in Fig. 1.
The pattern of Fig. 1, i.e., a large valley between the Sf and
the TCP curves, was also experimentally observed in direct
measurements of the survival fraction and of the TCP by
Kappler et al. [36] in megacolony assays after uniform
irradiation (Fig. 2). This general pattern is not related to the
cell type, but is related to the random energy deposition of
rays jointly with the high number of cells in tissues that
involves large absorbed dose in order to kill almost all
the cells.
The radiobiological computation using Eq. 2 and the
radiosensitivities measured in thyroid cell assays con-
firmed the result of the statistical analysis, i.e., that the
therapy to diagnostic uptake ratios can be explained by
the cell-killing fraction (Table 1). The computed uptake
reductions are even too large.
Lassman et al. reported mean absorbed doses ranging from
4 to 38 Gy (Table 3 in [7]) for a first 74 MBq 131I scan.
Rescaled to a 1.11 GBq 131I therapy without pre-therapy scan,
the mean absorbed dose typically ranges from 60 to 600 Gy.
Assuming uniform absorbed dose, such huge values should
provide a TCP equal to 100 %, higher than the 70–95 %
range reported in the literature [20–24]. Taking into account
the heterogeneous uptake, as measured in 124I PET [27] and
using a more sophisticated radiobiological model, the
computed survival fraction increased and provided uptake
reduction in line with the observations (see Additional file 1).
It is a real deficiency that in all the papers reporting the
stunning effect in vivo [1–6], except that of Lassmann et al.
[7], neither the absorbed doses nor the thyroid remnant
uptakes were assessed. Regarding the huge variation in
remnant uptakes due to the lesion type, but also due to the
hypo- or eu-thyroid status of the patient, doses estimation
is required to avoid blurring of the observations that could
lead to misunderstanding of the physical effects.




















Fig. 2 Cell survival fraction Sf and TCP measured by Kappler et al. after uniform irradiation of sarcoma megacolony assays (5 × 104 cells)
(curves Lu-siRNA in Figs. 5 and 6 of [31]: cells were radio-sensitized by RNA transfection). The much larger number of cells in actual lesions
(>107→Sf < 10−8 for TCP = 0.9) still dramatically widens the width of the valley in between the two curves as shown in Fig. 1
Table 1 Summary of reported and computed data
Uptake min–max Cells tum.–nor. Uptake ratio Dose dist. uniform
A (MBq) D (Gy) α (Gy−1) αD Sf Eq. 2
A (MBq) D (Gy) α (Gy−1) αD Sf Eq. 2
124I [26] 74 2.1–23.7 0.37–0.97 0.78–23.0 0–0.46
131I [7] 74 4.0–38.0 0.37–0.97 1.48–36.9 0.08–1.00 0–0.23
131I [6] 120 6.5–61.6 0.37–0.97 2.41–59.8 0.05–0.83 0–0.09
123I [6] 200 0.1–1.3 1.85–4.85 0.19–6.3 0.17–0.86 0–0.83
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The present study shows that the cell-killing fraction is
sufficient to explain the observed reductions in uptake,
and that even if some living cells express a stunning effect
just after irradiation (as shown in vitro [15–17]), they will
mostly die with time. In other words, the pre-therapy scan
appears to be itself a first therapy cycle. As the β/α value
is very low (0.02 ± 0.03 Gy−1 [27]), no significant reduction
of the therapeutic efficiency should result from this
absorbed dose fractionation. This is in line with several re-
cent studies reporting that the uptake reduction does not
impact the 131I therapy outcome [4, 37–40].
However, one has to keep in mind that in lesions ex-
pressing huge uptake heterogeneity, the low pre-therapy
activity could kill cells with high uptakes without killing
by cross firing surrounding cells with low uptakes. After-
wards, these cells with high uptake will no longer take 131I
up during the main therapy session (because most are
killed), reducing by this way the cross irradiation that the
cells with low uptake could have received. This cell type
selection occurring during the pre-therapy scan could
explain lower rates of ablation success reported in some
studies [41, 42].
Conclusions
The pure statistical analysis supports that the so-called
thyroid stunning effect can be explained by the cell-killing
fraction. This result is confirmed by the quantitative radio-
biological analysis based on normal and tumor cells radio-
sensitivities measured on human thyroid cell assays.
The study also shows that the two radioiodine isotopes
(131I, 123I) induce an uptake reduction after a low activity
scan and that it could be the case for 124I too. As the β/
α value is very low, this effective fractionation of the
therapy should not impact the patient outcome, in
agreement with recent studies. However in case of huge
uptake heterogeneity, pre-therapy scan could specifically
kills high-uptake cells and by the way could reduce the
cross irradiation to the low uptake cells during the ther-
apy, resulting in a reduction of the ablation success rate.
Additional file
Additional file 1: Prediction of the uptake reduction after a first low
activity 131I or 123I scan observed by Hilditch et al. [6] and Lassmann
et al. [7] using the thyroid cells radiosensitivity [26] jointly with the
non-uniform uptake in tissue observed in 124I PET [27]. (DOCX 102 kb)
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SW found the statistical and radiobiological analysis. SW and MH performed
the mathematical and numerical computations. FJ handled the biological,
physiological and medical aspects of the study. All authors participated to
the paper writing. All authors read and approved the final manuscript.
Acknowledgements
We thank Dr. G Demonceau and Dr. N Leners for valuable discussions that
motivated this study, we are much thankful to Prof. A Nahum who brought
to our attention the important issue of thyroid absorbed dose heterogeneity.
This study was not funded.
The authors have no conflict of interest to disclose.
This article does not contain any studies with human participants performed
by any of the authors.
No animal was involved in this study.
Received: 19 August 2015 Accepted: 10 November 2015
References
1. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large
dose on subsequent uptake of therapeutic radioiodine in thyroid cancer
patients. Int J Rad Appl Instrum B. 1986;13:277–9.
2. McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of
therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated
thyroid cancer. Nucl Med Commun. 1997;18:505–12.
3. Bajén MT, Mañé S, Muñoz A, Garcia JR. Effect of diagnostic dose of 185 MBq
131I on postsurgical thyroid remnants. J Nucl Med. 2000;41:2038–42.
4. Dam HQ, Kim SM, Lin HC, Intenzo CM. 131I therapeutic efficacy is not influenced
by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527–33.
5. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine,
and the controversy of “thyroid stunning”. Nucl Med Commun. 2004;25:883–9.
6. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS.
Self-stunning in thyroid ablation: evidence from comparative studies of
diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging. 2002;29:783–8.
7. Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic
activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–25.
8. Woolfenden JM. Thyroid stunning revisited. J Nucl Med. 2006;47:1403–5.
9. Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM. The so-called
stunning of thyroid tissues. J Nucl Med. 2006;47:1406–12.
10. Gerard SK, Park HM. Stunning effect. J Nucl Med. 2007;48:328–9. author
reply: 329-330.
11. Hilditch TE, Bolster AA, Dempsey MF, Reed NS. The so-called stunning of
thyroid tissue. J Nucl Med. 2007;48:675–6. author reply: 676.
12. Filesi M, Colandrea M, Montesano T, D'Apollo R, Ronga G. Thyroid stunning
in clinical practice: is it a real problem? Minerva Endocrinol. 2008;34:29–36.
13. Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of
iodine, and the controversy of “thyroid stunning.”. Nucl Med Commun.
2004;25:883–9.
14. McDougall IR, Iagaru A. Thyroid stunning: fact or fiction? Semin Nucl Med.
2011;41:105–12.
15. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G,
et al. Stunning of iodide transport by 131I irradiation in cultured thyroid
epithelial cells. J Nucl Med. 2002;43:828–34.
16. Lundh C, Nordén M, Nilsson M, Forssell-Aronsson E. Reduced iodide
transport (stunning) and DNA synthesis in thyrocytes exposed to low
absorbed doses from 131I in vitro. J Nucl Med. 2007;48:481–6.
17. Nordén MM, Larsson F, Tedelind S, Carlsson T, Lundh C, Forssell-Aronsson E,
et al. Down-regulation of the sodium/iodide symporter explains 131I-
induced thyroid stunning. Cancer Res. 2007;67:7512–7.
18. http://www.doseinfo-radar.com/OLINDA.html. Accessed 13 November
2015.
19. Lundh C, Lindencrona U, Postgård P, Carlsson T, Nilsson M, Forssell-
Aronsson E. Radiation-induced thyroid stunning: differential effects of (123)I,
(131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression
in cultured thyroid cells. J Nucl Med. 2009;50:1161–7.
20. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, et al. Low- or high-dose
radioiodine remnant ablation for differentiated thyroid carcinoma:
a meta-analysis. J Clin Endocrinol Metab. 2013;98:1353–60.
21. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia
C, et al. Post-surgical thyroid ablation with low or high radioiodine activities
results in similar outcomes in intermediate risk differentiated thyroid cancer
patients. Eur J Endocrinol. 2013;169:23–9.
22. Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, et al. Effects of
low-dose and high-dose postoperative radioiodine therapy on the clinical
outcome in patients with small differentiated thyroid cancer having
microscopic extrathyroidal extension. Thyroid. 2014;24:820–5.
Walrand et al. EJNMMI Research  (2015) 5:67 Page 5 of 6
23. Du P, Jiao X, Zhou Y, Li Y, Kang S, Zhang D, et al. Low versus high
radioiodine activity to ablate the thyroid after thyroidectomy for cancer:
a meta-analysis of randomized controlled trials. Endocrine. 2015;48:96–105.
24. Abdulrezzak U, Tutus A, Isik I, Kurt Y, Kula M. The quantitative comparison
of low dose and standard dose radio iodine therapy effectiveness in
patients with low risk differentiated thyroid cancer. Q J Nucl Med Mol
Imaging. 2015 Jan 20. [Epub ahead of print]
25. Brahme A, Agren AK. Optimal dose distribution for eradication of
heterogeneous tumors. Acta Oncol. 1987;26:377–85.
26. Gaussen A, Legal JD, Beron-Gaillard N, Laplanche A, Travagli JP, Caillou B,
et al. Radiosensitivity of human normal and tumoral thyroid cells using
fluorescence in situ hybridization and clonogenic survival assay. Int J Radiat
Oncol Biol Phys. 1999;44:683–91.
27. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al.
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET
and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med.
2004;45:1366–72.
28. Nahum AE. Converting dose distributions into tumour control probability.
IAEA 1996 http://www.iaea.org/inis/collection/NCLCollectionStore/_Public/
28/018/28018201.pdf#page=26 Accessed 13 November 2015.
29. McParland BJ. Nuclear medicine radiation dosimetry: advanced theoretical
principles. New York: Springer; 2010. p. 449.
30. The 2007 recommendations of the international commission on radiological
protection. ICRP publication 103. Ann ICRP. 2007; 37:1-332
31. Barendsen GW, Walter HM. Effects of different ionizing radiations on human cells
in tissue culture. IV modification of radiation damage. Rad Res. 1964;21:314–29.
32. Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide
in man: refinement of current ICRP dosimetry models. Cancer Biother
Radiopharm. 2003;18:445–50.
33. Gibson WG, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the
human thyroid. Am J Pathol. 1982;106:388–93.
34. Medvedec M. Seeking a radiobiological explanation for thyroid stunning.
Eur J Nucl Med. 2001;28:393–5.
35. Modoni S, Martino G, Valle G, Perrone E, Frusciante V. How is thyroid
remnant ablation affected by former 131-1 diagnostic doses and/or elapsed
time? Eur J Nucl Med Mol Imaging. 2000;27:1152.
36. Kappler M, Rot S, Taubert H, Greither T, Bartel F, Dellas K et al. The effects of
knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the
radiosensitization in a soft tissue sarcoma cells in vitro under different
oxygen conditions. Cancer Gene Ther. 2007;14:994–1001.
37. Amin A, Amin M, Badwey A. Stunning phenomenon after a radioactive
iodine- 131I diagnostic whole-body scan: is it really a point of clinical
consideration? Nucl Med Commun. 2013;34:771–6.
38. El-Saban K, Al-Sakhri H, Al-Zahrani A. Effect of stunning of diagnostic 131-
iodine doses on ablative doses for differentiated thyroid cancer patient’s
outcome. J Sol Tum. 2013;3:11–9.
39. Yap BK, Murby B. No adverse affect in clinical outcome using low
preablation diagnostic (131)i activity in differentiated thyroid cancer:
refuting thyroid-stunning effect. J Clin Endocrinol Metab. 2014;99:2433–40.
40. Etchebehere EC, Santos AO, Matos PS, Assumpção LV, Lima MC, Lima MC,
et al. Is thyroid stunning clinically relevant? A retrospective analysis of 208
patients. Arq Bras Endocrinol Metabol. 2014;58:292–300.
41. Hu YH, Wang PW, Wang ST, Lee CH, Chen HY, Chou FF, et al. Influence of
131I diagnostic dose on subsequent ablation in patients with differentiated
thyroid carcinoma: discrepancy between the presence of visually apparent
stunning and the impairment of successful ablation. Nucl Med Commun.
2004;25:793–7.
42. Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW. The success of 131I
ablation in thyroid cancer patients is significantly reduced after a diagnostic
activity of 40 MBq 131I. Nuklearmedizin. 2009;48:138–42.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Walrand et al. EJNMMI Research  (2015) 5:67 Page 6 of 6
